Aysan Moeinafshar, Amir Reza Barati, Sahand Tehrani Fateh, Mohammad Taha Pahlevan Fallahy, Alireza Soltani Khaboushan
{"title":"Artificial Intelligence in Diagnosis and Prognosis of Cognitive Impairment in Parkinson's Disease.","authors":"Aysan Moeinafshar, Amir Reza Barati, Sahand Tehrani Fateh, Mohammad Taha Pahlevan Fallahy, Alireza Soltani Khaboushan","doi":"10.1159/000547180","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD), a progressive neurodegenerative disorder, affects millions globally, with cognitive impairment as a significant non-motor complication. These cognitive changes, ranging from mild cognitive impairment (MCI) to severe dementia, drastically reduce quality of life and worsen prognosis. Early and accurate detection is critical for effective management and therapeutic interventions. Recent advancements in artificial intelligence (AI) offer novel solutions for diagnosing, predicting, and managing cognitive deficits in PD by integrating diverse data modalities, including neuroimaging, electrophysiology, kinetic markers, and laboratory biomarkers. Prominent AI techniques, such as support vector machines, random forests, and convolutional neural networks have demonstrated high accuracy in analyzing multimodal data for cognitive profile prediction. Additionally, AI supports the development of personalized treatment strategies, both pharmacological and non-pharmacological, and enhances accessibility through telemedicine initiatives. Despite these advancements, challenges persist in standardizing methodologies, improving model interpretability, and integrating AI tools into clinical practice. Overcoming these hurdles will require robust validation studies and multidisciplinary collaboration. This review examines the transformative role of AI in analyzing multimodal datasets to classify cognitive impairments, predict disease progression, and identify therapeutic targets, paving the way for personalized, patient-centered care in PD management.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-44"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547180","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Parkinson's disease (PD), a progressive neurodegenerative disorder, affects millions globally, with cognitive impairment as a significant non-motor complication. These cognitive changes, ranging from mild cognitive impairment (MCI) to severe dementia, drastically reduce quality of life and worsen prognosis. Early and accurate detection is critical for effective management and therapeutic interventions. Recent advancements in artificial intelligence (AI) offer novel solutions for diagnosing, predicting, and managing cognitive deficits in PD by integrating diverse data modalities, including neuroimaging, electrophysiology, kinetic markers, and laboratory biomarkers. Prominent AI techniques, such as support vector machines, random forests, and convolutional neural networks have demonstrated high accuracy in analyzing multimodal data for cognitive profile prediction. Additionally, AI supports the development of personalized treatment strategies, both pharmacological and non-pharmacological, and enhances accessibility through telemedicine initiatives. Despite these advancements, challenges persist in standardizing methodologies, improving model interpretability, and integrating AI tools into clinical practice. Overcoming these hurdles will require robust validation studies and multidisciplinary collaboration. This review examines the transformative role of AI in analyzing multimodal datasets to classify cognitive impairments, predict disease progression, and identify therapeutic targets, paving the way for personalized, patient-centered care in PD management.
期刊介绍:
As a unique forum devoted exclusively to the study of cognitive dysfunction, ''Dementia and Geriatric Cognitive Disorders'' concentrates on Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field.